Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study

Lavery, A; Stevenson, L; McManus, D; Logan, GE; Walker, SM; Jellema, GL; Van Schaeybroeck, S; Virdee, PS; Middleton, MR; Elhussein, L; Turbitt, J; Colinson, D; Miedzybrodzka, Z; Petty, RD; Harkin, PD; Kennedy, RD; Eatock, MM; Thomas, AL; Turkington, RC

Conference item

Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study

Publication status:: Published

Peer review status:: Reviewed (other)

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Lavery, A., Stevenson, L., McManus, D., Logan, G. E., Walker, S. M., Jellema, G. L., Van Schaeybroeck, S., Virdee, P. S., Middleton, M. R., Elhussein, L., Turbitt, J., Colinson, D., Miedzybrodzka, Z., Petty, R. D., Harkin, P. D., Kennedy, R. D., Eatock, M. M., Thomas, A. L., & Turkington, R. C. (2020). Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study. Journal of Clinical Oncology, 38(15S), 4539–4539.

MLA Style

Lavery, A., et al. “Translational Analysis of Esophageal Adenocarcinoma (EAC) Patients Treated with Oxaliplatin and Capecitabine (Xelox) +/- the Dual ErbB Inhibitor AZD8931 in the DEBIOC Study.” Journal of Clinical Oncology, vol. 38, no. 15S, American Society of Clinical Oncology, 2020, pp. 4539–39.

Chicago Style

Lavery, A, L Stevenson, D McManus, GE Logan, SM Walker, GL Jellema, S Van Schaeybroeck, et al. 2020. “Translational Analysis of Esophageal Adenocarcinoma (EAC) Patients Treated with Oxaliplatin and Capecitabine (Xelox) +/- the Dual ErbB Inhibitor AZD8931 in the DEBIOC Study.” In Journal of Clinical Oncology, 38:4539–39. American Society of Clinical Oncology.
Share
Print